Table 1.

Patient characteristics. Tabular overview on clinical data of the ten included PCFBCL patients and two further arbitrary cases (cases #2 and #3)—being finally reclassified as PCMZL—with immunohistochemical and molecular findings of respective analyzed tissue specimen.

Pat ID	Sex	Age at Primary Diagnosis [Years]	Tumor Stage at Primary Diagnosis	Tumor Stage at Date Last Seen	Cutaneous Relapses	Number of Cutaneous Relapses	Systemic Dissemination	Treatment	Overall Survival Since Primary Diagnosis [Months]	Final Status	Clonality	bcl-2 Expression Immunohistochemistry	bcl2 FISH Analysis
1	male	39	T2 N0 M0	T2 N0 M0	yes	1	no	rituximab	117	alive	polyclonal	negative	negative
2	male	60	T2c N0 M0	T2c N0 M0	no		no	rituximab	75	dead	polyclonal	positive	negative
3	female	70	T2 N0 M0	T2 N0 M0	no		no	rituximab	131	alive	oligoclonal/polyclonal	positive	negative
4	male	54	T1 N0 M0	T2 N0 M0	yes	3	no	excision, radiation	200	alive	oligoclonal/polyclonal	negative	negative
5	female	70	T2 N0 M0	T2b N0 M0	yes	>5	no	excision, radiation, topical steroids, rituximab	117	alive	monoclonal	positive	negative
6	female	66	T1 N0 M0	T1 N0 M0	no		no	watch-and-wait	66	alive	not done	negative	negative
7	female	89	T1b N0 M0	T1b N0 M0	no		no	radiation	47	alive	not done	negative	negative
8	male	45	T1a N0 M0	T1a N0 M0	no		no	excision	23	alive	polyclonal	positive	negative
9	male	50	T1a N0 M0	T1a N0 M0	no		no	radiation	21	alive	not done	positive	positive
10	male	50	T1 Nx Mx	T1 Nx Mx	no		no	watch-and-wait	57	alive	monoclonal	negative	negative
11	female	53	T2 N0 M0	T2 N0 M0	yes	2	no	radiation, topical steroids	35	alive	not done	negative	negative
12	male	43	T2 N0 M0	T2 N0 M0	no		no	rituximab	107	alive	not done	negative	negative